A trial of brolitene in the treatment of spasticity.

Abstract

A new anti‐spasticity agent, brolitene, has been assessed in patients with spasticity of spinal or cerebral origin. Twenty‐seven patients were entered in a double‐blind cross‐over trial lasting 6 weeks, using a fixed dose of six tablets (1200 mg brolitene) per day. Clinical assessment failed to show any therapeutic effect in the seventeen patients completing the trial, except in one with multiple sclerosis. Ten patients had to be withdrawn from the trial, six while being treated with the active agent. 1976 The British Pharmacological Society